A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY OF PF-00489791 IN SUBJECTS WITH STAGE 1 AND 2 ESSENTIAL HYPERTENSION USING AMBULATORY BLOOD PRESSURE MONITORING (ABPM)
Latest Information Update: 14 Oct 2021
At a glance
- Drugs PF 489791 (Primary)
- Indications Essential hypertension; Hypertension
- Focus Therapeutic Use
- Sponsors Pfizer
- 25 Feb 2008 Status change from in progress to completed, as reported by clinicaltrials.gov.
- 11 Jan 2008 Status change from recruiting to in progress.
- 28 Dec 2007 The expected completion date for this trial is now 1 Jan 2008.